Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Platelet Aggregation Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Platelet Aggregation Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Platelets are one of the formed elements of blood, along with RBCs and WBCs and play a very important role in physiological hemostasis and thrombus formation. These inhibit the cascade steps in the primary hemostasis phase to pervert platelet plug formation inside the blood vessels, thus preventing the blocking of blood vessels. However, it is also a key pathophysiological factor in developing arterial ischaemic events, including coronary artery disease, cerebrovascular accidents, and peripheral arterial disease. Platelet Aggregation Inhibitors therapy finds a role in preventing recurrent events in individuals affected by one of these conditions. The very initial therapy was with Aspirin and Clopidogrel, which were the very initial drugs used to prevent platelet aggregation However, this landscape has changed dramatically with the advent of newer and more potent agents like Prasugrel and Ticagrelor. New classes of drugs like glycoprotein IIb/IIIa receptor antagonists have changed the market dynamics, which are more potent and reliable. According to the British Heart Foundation, there are about 620 million people living with heart and circulatory diseases globally. According to the U.S. Department of Health & Human Services, about 1 in 20 adults above the age of 20 are suffering from coronary artery disease (CAD) which accounts for 5% of the population of the USA. Several factors that are responsible for rising heart diseases are Changing lifestyles, High Blood Pressure, High Cholesterol levels, Unhealthy diet and/or overeating, Obesity, alcohol consumption, smoking, and others. A number of these antagonists are in the market while many are ongoing clinical trials. 34 companies have various products in their pipelines with 28 products in various stages of clinical trials. 6 products are in Phase 4, 7 products are in Phase 3, 4 products are in Phase 2 while 4 products are in Phase 1 of the clinical trials.
Key Developments:
Approved drugs
Drugs in Pipeline
Clinical Activity and Developments of Platelet Aggregation Inhibitors
Companies have their products in the pipeline in various phases of clinical trials with approximately 28 products for above 118 diseases.
|
Molecule name |
Number of studies |
|
Clotinab (Abciximab) |
58 |
|
Tyvaso (Treprostinil) |
29 |
|
Disgren (Triflusal) |
7 |
|
Indobufen |
7 |
|
Opalmon (Limaprost) |
3 |
Drugs like Clotinab (Abciximab) have shown encouraging results and are in the market for the treatment of various diseases as an adjuvant to Percutaneous coronary intervention for the treatment of cardiac ischaemic complications, unstable angina, and others, and Tyvaso(Treprostinil) is indicated for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise inability According to British Heart Foundation, it is estimated that 1 in every 13 people is living with a heart or circulatory disease globally in 2021. Therefore, the increase in the prevalence of these diseases is an opportunity for the market and is expected to act as the growth driver for the Platelet Aggregation Inhibitors market.
The number of people living with Heart and Circulatory diseases has doubled since 1997. Globally heart and cardiovascular diseases had a prevalence of 340 million in Asia and Australia, 48 million in North America, and 100 million in Europe in 2021. This is an alarming situation on a global scale. According to the Centres for Disease Control and Prevention, in the USA, more than 795,000 people have a stroke every year, whereas according to a research report, between 2017 and 2047, it is estimated that the number of people living with stroke in Europe will increase by 27%. Sales of Tyvaso by United Therapeutics Corporation were $166.5 million for the 4th quarter ending 2021 and $876 million for the whole financial year 2022, which was 46% more than the last financial year.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Clotinab (Abciximab), Tyvaso (Treprostinil), Disgren (Triflusal), Indobufan, and Opalmon (Limaprost) are some of the molecules approved by the FDA.
These are being used in various indications like Ischaemic Heart Disease, Heart failure, Pulmonary Hypertension, Strokes and others.
Pfizer, Isu Abxis, United Therapeutics Corporation, Meiji Holdings Co., Ltd., and Ono Pharmaceutical Co., Ltd. are some of the key market players for Platelet Aggregation Inhibitors.
Rising incidence of diseases and changing lifestyles leading to obesity and heart diseases are the key opportunities for Platelet Aggregation Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.